Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Account Payables (2022 - 2025)

Taysha Gene Therapies' Change in Account Payables history spans 4 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 48.48% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached $469000.0, up 117.72%, while the annual FY2024 figure was -$2.9 million, 27.23% down from the prior year.
  • Change in Account Payables for Q3 2025 was -$1.9 million at Taysha Gene Therapies, down from $3.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.0 million in Q1 2024 and bottomed at -$9.4 million in Q3 2022.
  • The 4-year median for Change in Account Payables is -$1.2 million (2023), against an average of -$736400.0.
  • The largest YoY upside for Change in Account Payables was 1008.64% in 2024 against a maximum downside of 191.55% in 2024.
  • A 4-year view of Change in Account Payables shows it stood at -$4.6 million in 2022, then skyrocketed by 73.19% to -$1.2 million in 2023, then dropped by 22.28% to -$1.5 million in 2024, then fell by 29.52% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Change in Account Payables are -$1.9 million (Q3 2025), $3.0 million (Q2 2025), and $923000.0 (Q1 2025).